Liver cancer study seeks immune clues to immunotherapy success
NCT ID NCT05044676
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if certain immune cells in the blood could predict which patients with advanced liver cancer would benefit from a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). Researchers planned to measure these cells before and after starting treatment in about 4 participants. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
4 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with an indication for treatment with Atezolizumab / Bevacizumab for the management of an advanced disciplinary hepatocellular carcinoma in a multidisciplinary consultation meeting (RCP).
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Advanced hepatocellular carcinoma with an indication of systemic therapy by Atezolizumab-Bevacizumab * At least one measurable untreated lesion * ECOS performance status of 0 or 1 Exclusion Criteria: * HIV/ immunosuppressive treatment * Active of history of autoimmune disease or immune deficiency * Priori history of liver transplantation or systemic porto shunt * Pregnant of breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
Paris, France, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
- AI-Enhanced ultrasound aims to catch liver cancer earlier
- Can turbocharged immune cells stop liver cancer from coming back?
- Two blood markers put to the test for early liver cancer detection
- New antibody pair takes aim at advanced liver cancer in major trial
- New antibody aims to preserve immune checkpoint while fighting cancer